Further clinical trials addressing the use of BRAF, BRAF/MEK, and MEK inhibitors for odontogenic tumor treatment are necessary to clarify their effectiveness, the advantages and disadvantages, actual efficacy, and best treatment regimen for the patients. This evidence concerns the gene MAP2K7 and odontogenic neoplasm.